KBI-BIOPHARMA-SA
KBI Biopharma SA (KBI) and Selexis SA, both JSR Life Sciences companies, announced today that an expanded, fully-integrated mammalian contract development and manufacturing services facility is now open and operational in Geneva, Switzerland.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220613005062/en/
The ~94,000 square-foot integrated KBI/Selexis state-of-the-art facility builds upon the companies’ existing market foothold by combining best-in-class cell line development (CLD) and expert mammalian cell manufacturing in a single location. KBI and Selexis leverage their expertise and efficient end-to-end services for biomanufacturing clients.
This expansion enables industry-leading delivery of client programs through increased quality, efficiency, and time savings across a diverse portfolio of molecule formats. Under one roof, KBI and Selexis provide cell line transfection through cGMP drug manufacturing with Selexis’ specialized high-titer mammalian cell line development technologies and services and KBI’s cGMP bulk drug manufacturing for clinical and commercial requirements.
“This expansion in Geneva will provide our global clients with streamlined capabilities to support mammalian-based therapies,” said Mark W. Womack, Chief Executive Officer for KBI Biopharma and Selexis SA. “With a single touchpoint for best-in-class cell line development, process development, and manufacturing, clients experience heightened access to our process and product-based expertise.”
He added, “This facility expansion, together with our track record in the space, strengthens our commitment to deliver a seamless experience to the European biopharmaceutical community and clients around the globe.”
The fully integrated Selexis and KBI development platform has supported more than 60 clinical development programs with high productivity and robust product quality. The two companies have developed a seamless approach, to optimize the client experience.
“We have always been a science-driven, customer-centric company. This expansion in Geneva helps our clients optimize their complex biomanufacturing processes under accelerated timelines,” said Ulrich Valley, Senior Vice President, Operations & Site Head, KBI Biopharma, Geneva.
The KBI Biopharma facility will create more than 200 technical positions in development, operations, and quality assurance. The facility includes a suite of analytical testing laboratories and dual 2,000L single-use cGMP manufacturing trains with downstream processes capable of producing 8-10 kg yields per batch.
With the expanded Geneva facility now operational, KBI and Selexis will celebrate with ribbon-cutting activities and facility tours starting in July 2022.
About KBI Biopharma, Inc.
KBI Biopharma SA is a wholly-owned subsidiary of KBI Biopharma, Inc., and a JSR Life Sciences company. KBI Biopharma is a leading global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. With each of its 500+ client partners, KBI works closely to personalize and accelerate drug development programs. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps clients advance drug candidates into the clinic and beyond. KBI serves its global clients with multiple locations in Europe and the USA. www.kbibiopharma.com .
About Selexis SA.
Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop, and commercialize innovative medicines and vaccines. Our global partners have utilized Selexis technologies to advance more than 158 drug candidates in preclinical and clinical development and manufacture ten commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220613005062/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SS&C Expands European Wealth Management Capabilities with New MiFID License in Ireland25.11.2025 13:00:00 CET | Press release
License enables SS&C to deliver integrated wealth management technology and services across the European Union from its Dublin hub SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced significant expansion of its European wealth management business with the establishment of SS&C Wealth Services Europe Ltd. The business has been granted authorization under the Markets in Financial Instruments Directive (MiFID) by the Central Bank of Ireland. The license strengthens SS&C’s ability to serve the European Union’s wealth management sector. The company can now deliver its full suite of technology-enabled wealth management solutions directly from Ireland. The new operation builds on SS&C’s successful U.K. wealth management business, creating a pan-European platform with advanced technology, deep regulatory expertise, and comprehensive servicing capabilities. Based in Dublin, the business will focus on helping financial institutions modernize and scale their wealth operations through
A-HEAT Allied Heat Exchange Technology AG mourns CEO Christian Weiser25.11.2025 13:00:00 CET | Press release
With deep sorrow, A-HEAT/Güntner announces the sudden and unexpected passing of Christian Weiser, CEO of A-HEAT Allied Heat Exchange Technology AG (A-HEAT). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251125106542/en/ Christian Weiser “We have lost a truly remarkable person. Christian Weiser was a leader of integrity, empathy, and humor. His tireless commitment helped to make the A-HEAT Group what it is today,” said Hubert Spegel, Member of the Board at A-HEAT. “Our thoughts and deepest sympathy go to his family, his loved ones, and all those who worked with him. We will honor his legacy and strive to continue his work with the same passion and conviction.” Throughout his decades-long career within the group, Christian Weiser held numerous leadership positions before being appointed CEO of A-HEAT. Under his leadership, the A-HEAT/Güntner Group expanded its global presence, strengthened its innovation and sustainability in
HCLTech Signs Strategic Collaboration Agreement With AWS to Accelerate Financial Services Industry Transformation With AI and Core Modernization25.11.2025 11:30:00 CET | Press release
HCLTech, a leading global technology company, today announced that it has signed a strategic collaboration agreement with Amazon Web Services (AWS) to accelerate innovation in the financial services industry through autonomous, AI-powered solutions. The collaboration brings together HCLTech’s deep domain expertise and AWS to deliver transformative outcomes for financial services organizations. “We understand that a digital journey is of strategic importance and the need of the hour is for a trusted partner that can engage across the transformation lifecycle,” said Srinivasan Seshadri, Chief Growth Officer and Global Head of Financial Services at HCLTech. “Financial institutions face increasing pressure to modernize their systems, deliver exceptional customer experiences, and meet sustainability requirements and many struggle with legacy infrastructure, siloed data, and complex regulatory requirements. Our collaboration with AWS addresses these challenges by providing proven solutions a
Bridgepoint to Partner With ht.digital, the Leading Digital Asset Transparency Layer25.11.2025 09:00:00 CET | Press release
Bridgepoint to become majority shareholder in ht.digital, a London headquartered specialist provider of audit, accounting, assurance, operational and technology solutions to the digital asset ecosystem ht.digital has delivered organic revenue growth of c.100% over the last two years, scaling rapidly in a fast-growing market The partnership will accelerate ht.digital’s international expansion and continued investment in technology, talent and brand Bridgepoint, one of the world’s leading mid-market investors, today announced that it has agreed to acquire a majority stake in ht.digital, a leading, London-headquartered provider of digital asset assurance and technology solutions. The investment will be made by Bridgepoint Development Capital V – Bridgepoint’s lower middle-market fund focused on supporting fast-growing businesses across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251125907148/en/ Digital assets – incl
Thredd Signs Landmark Agreement to Enable Visa Cloud Connect Globally25.11.2025 09:00:00 CET | Press release
Agreement sets stage for strengthened global reach, scalability, and resilience for fintechs and banks worldwide Thredd, a leading next-generation global payments processor, today announced that it has signed an agreement to enable Visa Cloud Connect on a global scale. This milestone reflects Thredd’s continued investment in cloud-first infrastructure and reinforces its role as a global technology leader in payments processing. Visa Cloud Connect allows organisations to access VisaNet, Visa’s secure and powerful global payments network, through their own cloud-based infrastructure. Purpose-built for cloud-native clients, Visa Cloud Connect can help deliver increased flexibility, faster time to market, and seamless scalability across borders. Under the agreement, Thredd will connect across three global Visa Cloud Connect endpoints, committing to a full global rollout. Once live, this will eliminate the need for multiple regional integrations, helping our clients gain new geographies and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom